Navigation Links
Elusys Awarded Additional $14.5 Million Under Existing U.S. Government Contracts Supporting Expanded Human Safety Studies of ETI-204 for Treatment of Inhalational Anthrax
Date:9/13/2012

PINE BROOK, N.J., Sept. 13, 2012 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing countermeasures for biodefense, announced today that it has been awarded additional funding from the U.S. Government, valued at $14.5 million, to support expanded human safety studies of ETI-204 (Anthim), an investigational agent for the treatment of anthrax infection following a biowarfare attack. The company has now received $149 million, under two advanced development contracts with a potential total value of $211 million, from the Biomedical Advanced Research and Development Authority, within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services. ETI-204 is an investigational anti-toxin and is a promising candidate for the treatment of inhalational anthrax in humans.

(Logo:  http://photos.prnewswire.com/prnh/20090420/NY01624LOGO )   

Anthrax is a life-threatening infectious disease caused by the bacterium Bacillus anthracis and remains one of the nation's top biowarfare threats. Much of the morbidity and mortality of anthrax can be attributed to anthrax toxins. Inhaled anthrax is often fatal, despite treatment with antibiotics.

The $14.5 million funding will be used to conduct final, expanded safety studies for intravenous (IV) administration of ETI-204, as well as a dose escalation safety study for intramuscular (IM) administration of the anti-toxin. IM administration would allow rapid administration of anti-toxin treatment to large numbers of people in an emergency setting. Elusys has also received funding previously from the U.S. Department of Defense to support the development of its IM formulation.

"As we continue to reach milestones in the late stages of our development program, we are pleased to have the ongoing support of the U.S. Government to evaluate not only IV administration but also the more rapid, cost-effective IM administration of ETI-204," said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys. "Advancing the development of both IV and IM administration of our anti-toxin could provide two important options in the prevention and treatment of inhalational anthrax following a biowarfare attack."

Elusys continues to work closely with the U.S. Food and Drug Administration (FDA) on the design of the ETI-204 Phase 3 development program in preparation for an anticipated End of Phase 2 meeting. ETI-204 was granted Fast Track status and Orphan Drug Designation in 2006 by the FDA.

About ETI-204

ETI-204 is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins by binding to Protective Antigen.  It is an investigational agent being developed for treatment of inhalational anthrax following a biowarfare attack.

ETI-204 efficacy and safety are being studied in animals and safety studies are being conducted with human volunteers. To date, five studies assessing the efficacy and safety of ETI-204 in animals with inhalational anthrax have been completed, and three studies assessing pharmacokinetics and safety of IV administration of ETI-204 in humans have been conducted. In the two completed studies, the adverse event profile of ETI-204 was comparable to placebo and the more common adverse events related to ETI-204 administration were headache and upper respiratory tract infection. ETI-204 is formulated as a solution suitable for either IV or IM administration. This program is supported with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services (HHS) under Contract Nos. HHSO100201000026C and HHS0100201100034C.

About Elusys Therapeutics, Inc.

Elusys Therapeutics, a private company based in Pine Brook, NJ, is focused on the development of antibody therapeutics for the treatment of life-threatening disease. Elusys has been engaged in development of biodefense countermeasures since 2000. The company has established experience in government contract management and to date has received multiple grants and has the potential to receive, in total, up to $211 million in government funding. ETI-204, a highly effective, anthrax anti-toxin, is in late-stage development and is a strong candidate for future procurement into the Strategic National Stockpile. For more information, please visit www.elusys.com.

SAFE HARBOR STATEMENT

This announcement includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.  This release includes forward looking statements.  Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements.  Such statements are based upon the current beliefs and expectations of management that are subject to risks, uncertainties and other important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements. The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Antigen Discovery Inc. Awarded Phase I SBIR Grant to Develop a Fully Integrated Microfluidic Point of Care Diagnostic Device
2. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
3. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
4. Biodel Awarded NIH Grant to Develop Concentrated Ultra-Rapid-Acting Insulin Formulations for Use in Artificial Pancreas
5. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
6. Turner Construction Company Awarded Fort Irwin Replacement Hospital
7. Spot On Sciences Awarded $1 Million DARPA Grant to Develop a Blood Sample Collection Device
8. Texas A&M System Awarded National Center for Innovation
9. Sorrento Therapeutics Awarded Third Phase I STTR Grant
10. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
11. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... LODI, N.J. , Feb. 4, 2016  Montoya ... Pinnacle Professional in the field of Pharmaceuticals. Montoya is ... . ... and supplies, Becton Dickinson provides healthcare institutions, ... medical equipment throughout fifty countries across the globe. ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... and competitive market to drive long-term market growth ... very common set of chronic disorders that affect ... disparate in terms of their symptoms and key ... by dysregulation of immune pathways and an inappropriate ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... Shark Finds and Kevin Harrington, ... a new DRTV campaign with Belly Bands. , Having a dog is great—except when ... puppy pads and find nothing works, get Belly Bands, the easiest way to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, ... much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on ... week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... in the 2015 Best in KLAS: Software & Services for HIT Implementation Support ... in KLAS report independently ranks vendor performance by healthcare executives, managers and clinicians ...
Breaking Medicine News(10 mins):